AtriCure Inc. (OQ:ATRC)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 7555 Innovation Way
MASON OH 45040-9695
Tel: N/A
Website: https://www.atricure.com
IR: See website
<
Key People
Scott William Drake
Independent Chairman of the Board
Michael H. Carrel
President, Chief Executive Officer, Director
Andrew Wade
Chief Financial Officer
Douglas J. Seith
Chief Operating Officer
Justin J. Noznesky
Senior Vice President, Marketing and Business Development
Salvatore Privitera
Chief Technology Officer
Business Overview
AtriCure, Inc. is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion. The Company also sells Lumitip dissectors and the Estech line of reusable cardiac surgery (valve) instruments. Its cryoICE cryosurgery product line offers various cryoablation devices. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage (LAA).
Financial Overview
For the three months ended 31 March 2020, AtriCure Inc. revenues decreased 1% to $53.2M. Net loss increased from $5.6M to $16.4M. Revenues reflect Minimally Invasive Ablation segment decrease of 15% to $6.6M, Open ablation -International segment decrease of 19% to $5.1M, Europe segment decrease of 12% to $5.9M, Asia segment decrease of 10% to $3.5M. Higher net loss reflects Selling, general and administrative increase of 17% to $39.3M (expense).
Employees: 730 as of Jan 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $1,920M as of Mar 31, 2020
Annual revenue (TTM): $230.07M as of Mar 31, 2020
EBITDA (TTM): -$30.52M as of Mar 31, 2020
Net annual income (TTM): -$45.97M as of Mar 31, 2020
Free cash flow (TTM): -$30.77M as of Mar 31, 2020
Net Debt Last Fiscal Year: $2.13M as of Mar 31, 2020
Shares outstanding: 44,054,294 as of May 14, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization